Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 37.00 | |
5 mg | In stock | $ 59.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 176.00 | |
50 mg | In stock | $ 297.00 | |
100 mg | In stock | $ 455.00 | |
200 mg | In stock | $ 657.00 | |
500 mg | In stock | $ 987.00 |
Description | DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. |
In vitro | DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer. |
In vivo | As determined by loss of body weight and death of treated mice,DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity[2]. |
Synonyms | N,N''-Carbonylbis[L-glutamic acid], (2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid |
Molecular Weight | 320.25 |
Formula | C11H16N2O9 |
CAS No. | 302941-52-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 280 mg/mL (874.32 mM)
H2O: 140 mg/mL (437.16 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DUPA 302941-52-2 Others PROTAC Ligands for Target Protein for PROTAC Target Protein-binding Moiety N,N''-Carbonylbis[L-glutamic acid] Inhibitor (2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid inhibit inhibitor